Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Nov 18, 2024Closes
Sep 7, 2026Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health
Eligible applicants: City or township governments, Special district governments, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Native American tribal governments (Federally recognized), Independent school districts, State governments, County governments, Small businesses, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, For profit organizations other than small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), Others (see text field entitled "Additional Information on Eligibility" for clarification)
Description
Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts.